RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Provention Bio Stock

Provention Bio Liabilities 2025

Provention Bio Liabilities

115.01 M USD

Ticker

PRVB

ISIN

US74374N1028

WKN

A2JRLW

In 2025, Provention Bio's total liabilities amounted to 115.01 M USD, a 0% difference from the 0 USD total liabilities in the previous year.

Provention Bio Aktienanalyse

What does Provention Bio do?

Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Provention Bio's Liabilities

Provention Bio's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Provention Bio's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Provention Bio's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Provention Bio's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Provention Bio’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Provention Bio stock

What is the level of liabilities of Provention Bio this year?

Provention Bio has a debt balance of 115.01 M USD this year.

What were the liabilities of Provention Bio compared to the previous year?

The liabilities of Provention Bio have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Provention Bio?

High liabilities can pose a risk for investors of Provention Bio, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Provention Bio?

Low liabilities mean that Provention Bio has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Provention Bio affect the company?

An increase in liabilities of Provention Bio can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Provention Bio affect the company?

A decrease in the liabilities of Provention Bio can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Provention Bio?

Some factors that can influence the liabilities of Provention Bio include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Provention Bio so important for investors?

The liabilities of Provention Bio are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Provention Bio take to modify the liabilities?

To change its liabilities, Provention Bio can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Provention Bio pay?

Over the past 12 months, Provention Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Provention Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Provention Bio?

The current dividend yield of Provention Bio is .

When does Provention Bio pay dividends?

Provention Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Provention Bio?

Provention Bio paid dividends every year for the past 0 years.

What is the dividend of Provention Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Provention Bio located?

Provention Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Provention Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Provention Bio from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.

When did Provention Bio pay the last dividend?

The last dividend was paid out on 10/7/2025.

What was the dividend of Provention Bio in the year 2024?

In the year 2024, Provention Bio distributed 0 USD as dividends.

In which currency does Provention Bio pay out the dividend?

The dividends of Provention Bio are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Provention Bio stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Provention Bio

Our stock analysis for Provention Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provention Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.